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The cell cycle is a tightly regulated process controlled by the conserved cyclin-dependent 
kinase (CDK)–cyclin protein complex1. However, control of the G0/G1 transition 
remains incompletely understood. Here, we demonstrate that p38 mitogen-activated 
protein kinase (MAPK) gamma (p38γ) acts as a CDK-like kinase and thus cooperates 
with CDKs, regulating entry into the cell cycle and sharing high sequence homology, 
inhibition sensitivity, and substrate specificity with CDK family members. In hepatocytes, 
p38γ induces proliferation after partial hepatectomy (PHx) by promoting Rb 
phosphorylation on known CDK target residues. Lack of p38γ or treatment with the p38
γ inhibitor pirfenidone protects against chemically-induced liver tumour formation. 
Furthermore, human hepatocellular carcinoma (HCC) biopsies show high p38γ
expression, suggesting p38γ as a potential target for HCC therapy.
Despite the identified role of CDKs in cell cycle progression, the precise molecular 
mechanisms that trigger cell cycle initiation are unknown in most cell types. The
p38MAPKs (p38, β, γ and δ) and the CDKs belong to the CMGC protein kinase 
superfamily2. Sequence analysis of catalytic domains shows that the p38 MAPKs form a 
sister group within the CDK family (Extended data Fig. 1a). A heuristic three-
dimensional (3D) search of active CDK1/2 highlighted a higher degree of structural 
similarity with p38γ than with other stress kinases (Suplemmentary Table 1). 
Molecular dynamics (MD) simulations revealed a similar affinity of the CDK1 inhibitor 
RO3306 for the ATP-binding sites of p38γ and CDK1 stronger than for CDK2 or p38δ,
with no affinity towards p38. This suggests that p38γ and CDK share similar inhibition 
mechanisms (Extended data Fig. 1b-e, and videos 1, 2). 
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To test whether these kinases share common substrates, we studied retinoblastoma
tumour suppressor protein (Rb). Rb remains hypophosphorylated and active in G0, but 
during cell cycle progression it is sequentially phosphorylated by CDKs, leading to its 
inactivation promoting cell cycle entry and proliferation3. In vitro kinase assays revealed 
that p38γ equally phosphorylatesd Rb at twelve CDK target residues3 (Extended data 
Fig. 1f, 2a). Moreover, we detected Rb in immunoprecipitates of p38γ in liver lysates 
(Fig. 1a). p38γ-mediated Rb phosphorylation in vivo was confirmed in liver from p38γ-/-
(p38γ KO) mice infected with liver-specific adeno-associated viruses expressing a 
constitutively active form of p38γ (AAVp38γ*) (Fig. 1b). These data indicate that p38γ
presents similarities with CDKs, sharing structural homology, comparable binding 
dynamics for RO3306 in the ATP-binding site, and a similar substrate specificity.
Phosphorylation-induced Rb inactivation in hepatocytes is sufficient to promote G0/G1 
transition4,5. After PHx, a well-established model of hepatocyte proliferation, p38γ was 
phosphorylated and activated (Fig. 1c). To address the physiological impact of p38γ-
mediated Rb phosphorylation after PHx, we compared hepatocyte proliferation in mice 
lacking p38γ in hepatocytes (AlbCRE-p38γ mice) and in control AlbCRE mice (Alb-
CRE+/−). Whereas PHx induced Rb phosphorylation in control mice, this effect was 
abolished in AlbCRE-p38γ mice (Fig. 1d) without changes in CDK expression 
(Extended data Fig. 2b). Loss of Rb phosphorylation in AlbCRE-p38γ mice correlated 
with lower induction of cyclin E and A (Extended data Fig. 2b). Compared with 
AlbCRE mice, AlbCRE-p38γ mice also showed markedly reduced hepatic DNA 
synthesis and hepatocyte proliferation, measured by BrdU incorporation, Ki67-
immunostaining and PCNA expresion (Fig. 1e-g). The lower hepatocyte proliferation in
AlbCRE-p38γ mice was reflected in lower liver regeneration (Fig. 1h Extended data 
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Fig. 3a). Together, these results indicate that p38γ is required in hepatocytes for Rb 
phosphorylation and liver regeneration.
To corroborate these results and avoid the effects of  unspecific deletion of p38γ, we 
infected AlbCRE-p38γ with AAVp38γ*. The hepatocyte-specific expression of active 
p38γ recovered hepatocyte proliferation, Rb phosphorylation, and liver regeneration 
(Extended data Fig. 3 b-f). N-terminal Rb phosphorylation by p38 delays cell-cycle 
progression, rendering Rb insensitive to CDK regulation6. Unlike hepatocyte-specific 
active p38, active p38γ promoted phosphorylation of the Rb C terminus and hepatocyte 
proliferation (Extended data Fig. 3g-h).
Lack of p38γ impaired liver regeneration although did not affect survival (Extended 
data Fig. 4a). This is consistent with peak Rb phosphorylation and hepatocyte 
proliferation, which occurred at 60h post PHx (Extended data Fig. 4b and 4f). p38, 
the p38 isoform most closely related to p38γ, can compensate the lack of p38γ and 
phosphorylate its substrates7-9. p38 expression increased in AlbCRE-p38γ mice after
PHx (Extended data Fig. 4c), and the lack of both kinases in hepatocytes (AlbCRE-p38
γδ) abolished Rb phosphorylation and significantly delayed hepatocyte proliferation 
(Extended data Fig. 4d-h).
Stress-activated p38γ-mediated cell cycle regulation is not restricted to hepatocytes since 
p38γ also phosphorylates Rb in gut epithelial cells treated with dextran sulfate sodium 
(Extended data Fig. 5).
The precise mechanism by which Rb is phosphorylated in vivo remains unclear because 
single genetic ablation of CDK2 or CDK1 does not block hepatocyte DNA replication 
during liver regeneration10,11. In vitro kinase assays with CDK2 and p38γ* showed that 
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more Rb residues were phosphorylated when both kinases were used, suggesting that 
these kinases work in concert to control Rb phosphorylation (Extended data Fig. 6a). 
Immunoprecipitation analysis confirmed interaction between p38γ and CDK2 in 
hepatocytes (Extended data Fig. 6b-c). To explore the cooperation between p38γ and 
CDK2, we examined the kinase activation after PHx. p38γ was activated just 4 hours 
after PHx, increasing its binding and the phosphorylation of Rb at Ser795 and 
Ser821/826. Moreover, a second p38γ activation peak was detected after 24 hours with 
Rb phosphorylation on residues Ser807/811 and Ser780, preceding the proliferation
detected by BrdU incorporation (Fig. 2a and Extended data Fig. 6d). Interaction
between CDK2 and p38γ increased during these two p38γ activation peaks (Fig. 2a). 
These results correlate with a stronger interaction between CDK1/2 and Rb when p38γ is 
present (Extended data Fig. 6e), whereas p38γ binding to Rb was independent of 
CDK1/2 (Extended data Fig. 6c). Moreover, studies with a nonphosphorylatable Rb
mutant12 indicated that Rb phosphorylation is required for its binding to CDK2 
(Extended data Fig. 6f).
In addition, p38γ was able to compensate the loss of CDK1 or CDK2 as infection with 
AAVp38γ* rescued Rb phosphorylation after CDK1/2 silencing or ablation and fully 
preserved hepatocyte proliferation and hepatic DNA synthesis in the livers of CDK1/2-
depleted mice (Fig. 2b-d and Extended data Fig. 6g-i). Collectively, these results 
suggest that p38γ controls hepatocyte proliferation through the regulation of Rb 
phosphorylation and likely induces proliferation through cooperation with classical 
CDKs. Moreover, infection with AAVp38γ* rescued Rb phosphorylation and 
proliferation after silencing of CDK4 and CDK6 (Extended data Fig. 6j-m), confirming 
the ability of p38γ to phosphorylate Rb in the absence of these CDKs.
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CDK1 ablation protects against liver tumourigenesis13. Interestingly, there are similar
CDK1 and p38γ mutation rates in human HCC samples (Extended data Fig. 7a) and the 
mutations located in the L16 loop of p38γ induce its activation14. Moreover, p38γ
expression was higher in human HCC cell lines than in primary hepatocytes (Extended 
data Fig. 7b) and was activated in liver from genetically engineered HCC mouse models 
(Extended data Fig. 7c). Most importantly, p38γ staining was far stronger in human 
HCC biopsies than in non-tumour tissues (Fig. 3a and Extended data Fig. 7d). In 
addition, p38γ expression directly correlated with actin and collagen (col1a), markers of 
fibrosis that usually precede the development of liver cancer (Fig. 3b and 
Suplemmentary Table 2); moreover, high p38γ expression was associated with worse 
outcome in liver cancer (Fig. 3c). In agreement, p38γ knockdown attenuated 
proliferation and colony formation in the HCC cell lines (Extended data Fig. 8). These 
findings may indicate an involvement of p38γ in human liver tumour development.
In agreement, p38γ was activated after DEN injection and its deficiency markedly 
attenuated DEN-induced Rb phosphorylation and compensatory proliferation, correlating
with lower PCNA expression and hepatocytes proliferation (Extended data Fig. 9a-c). 
Moreover, HCC was strongly suppressed in AlbCRE-p38γ mice, which had smaller and 
fewer tumours and improved survival than AlbCRE mice (Fig. 3d-g).
AlbCRE-p38γ mice were also protected against carbon tetrachloride (CCl4)- and
streptozotocin (STZ)/HFD-induced liver cancer (Extended data Fig. 9d-g). We next 
evaluated the effect on liver tumourigenesis of p38γ inactivation. The inhibitor 
pirfenidone bound to and inhibited p38γ without affecting CDK2 activity (Fig. 4a and 
Extended data Fig. 10a-b), and reduced hepatic DNA synthesis in WT mice but not in 
AlbCRE-p38γ mice, indicating a p38γ-mediated effect (Fig. 4b). Without evident 
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secondary effects, pirfenidone reduce the number an size on liver tumours in DEN-
treated mice and improved its survival (Fig. 4c-e and Extended data Fig. 10c). 
Moreover, specific ablation of p38γ using AAV2/8-CAG-Cre once the tumours were 
already established confirmed the therapeutic effects of p38γ inhibition (Extended data 
Fig. 10d-g). Interestingly, those tumours that grow in the pirfenidone-treated mice had 
lost Rb expression (Fig. 4f), suggesting that upon pirfenidone treatment only tumours
lacking Rb are able to proliferate. These data are consistent with the inactivation of 
tumor suppressors such as Rb through chromosomal mutations during tumour
development15, thus indicating that pirfenidone will be effective against HCC tumours 
that maintain Rb expression.
Our results show that p38γ MAPK functions as a CDK-collaborating protein; similarly to 
the role of MAPK in CDK signaling recently established in yeast16. p38 MAPK protein 
family members fall into two categories: p38 and p38β on one hand and p38γ and p38δ
on the other17. All members share the same mechanism of activation by upstream MAPK
kinases; however, the two p38 classes do not share substrate specificity or inhibitor
selectivity. p38 increases cell survival by N-terminal phosphorylation of Rb, which 
renders Rb insensitive to inactivation by CDKs6. Consequently, p38 deletion in 
hepatocytes results in increased HCC development18. These results reinforce the idea that 
different p38s can have opposing functions19.
We demonstrated that p38γ is sufficient to induce cell cycle entry even when CDKs
expression is downregulated. This might allow a cell cycle regulation different from the 
canonical mitogenic signal/CDK activation pathway, via stress damage/p38γ activation, 
thereby exerting tight regulation on the cell cycle.
This study suggests that a non-classical CDK could initiate the cell cycle in a cyclin 
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independent manner in quiescence, when CDK/cyclin complexes are less abundant. p38γ
may represent a unique kinase that enables cells to escape from quiescence in response to 
stress stimuli. The confirmation that p38γ is essential for Rb-dependent cell cycle 
progression and liver tumourigenesis strongly supports the potential of p38γ as a 
therapeutic target in HCC, opening a new avenue in the fight against this incurable 
disease.
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FIGURE LEGENDS 
Figure 1: p38γ phosphorylates Rb and promotes liver proliferation after PHx.
a, Immunoprecipitation from control livers (AlbCRE mice) and AlbCRE-p38γ mice (liver-
specific p38γ KO) treated with DEN for 48h using anti-p38γ or IgG (control). b, p38γ
KO mice injected with adeno-associated virus (AAV8/9) expressing active p38γ (p38γ*). 
Liver immunoblot. c-g, AlbCRE and AlbCRE-p38γ mice 48h after PHx or SHAM 
procedure c-d, Liver immunoblot e, BrdU immunostaining.  n=3-7. f, Ki67 
immunostaining. n=4-6. g, PCNA immunoblot. h, Liver-to-tibia length ratio. (n=3-8). All 
quantification shown as mean ± SEM. Comparisons were made by two-sided Student t-
test or one-way ANOVA coupled to the Bonferroni post-test **, P<0.01; ***, P<0.001.
Scale bars, 100μm. 
Figure 2: p38γ compensates the loss of CDK1/2.
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 a, WT mice subjected to PHx were sacrificed at the indicated time points. Liver lysated 
immunoprecipitated with anti-p38γ. b-d, WT and CDK1/2 KO (AAV2/8-Cre) mice 
infected with or without active p38γ (AAV p38γ*) were subjected to PHx or SHAM. b,
Immunoblot analysis. c, BrdU immunostaining. n=4-7 (one-way ANOVA); *, P<0.05. e, 
Ki67 immunostaining. n= 3-5 fields from AlbCRE mice 0h n= 7, 48h n=7; AlbCRE-p38γ
0h n=3, 48 n=3; AlbCRE-p38γ AAV p38γ* 0h n=3, 48h n=3. (one-way ANOVA 
coupled to Kruskal-Wallis post-tests); *, P<0.05. Scale bars, 500μm. All quantification 
shown as mean ± SEM. 
Figure 3: p38γ drives HCC development.
a, p38γ immuno-staining in human HCC or healthy livers. Scale bar, 500 μm. b,
Pearson´s correlation of mRNA levels in human livers (n=107). c, Kaplan-Meier survival 
curves of patients stratified by p38 expression n=372. d-f, DEN-induced HCC in 6-
month-old. d, Arrows mark tumours. e, Number of tumours and f, Tumour size n=5-11. 
g, Kaplan-Meier analysis of survival n=10-11 **P<0.01. Scale bar, 100 μm. All 
quantification shown as mean ± SEM. Comparisons were made by two-sided Student t-
test, Mann Whitney U test or Mantel-Cox log-rank test
Figure 4: Pirfenidone inhibits p38γ activity and protects against DEN-induced 
HCC.
a, Liver immunoblot 2 weeks after acute DEN treatment. b, Ki67 immunohistochemistry 
in pirfenidone-treated mice before PHx. n=5-17 (one way ANOVA); ***, P<0.001. c-e, 
11 months DEN-treated mice with or without pirfenidone treatment. c, MRI d, Tumour 
number; total and maximum tumour volume per mouse (n=20-13), analysed at from MR 
images using OsiriX software; (Mann-Whitney test); *, P< 0.05. e, Kaplan-Meier 
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analysis of survival; (Mantel-Cox log-rank test); ***, P< 0.001; n=9-6. f, Immunoblot 
analysis in hepatic tumours (T) and lesion-free peritumour zones (L) in mice treated as in 
d-f. All data are mean ± SEM. 
MATERIALS AND METHODS
Study population and sample collection
Immunohistochemical staining of p38γ was performed in liver samples from 46 patients 
(86.1% male, mean age: 69.2 years, standard deviation [SD]: 22.6 years) and 11 controls 
(36.4% male, mean age: 45.9 years, standard deviation [SD]: 14.7 years) recruited at the 
University Hospital of Salamanca, Spain. Patients were diagnosed with hepatocellular 
carcinoma by liver biopsy, and control individuals were recruited from patients who 
underwent laparoscopic cholecystectomy for gallstone disease and had no laboratory or 
histopathological evidence of other liver diseases. This study was approved by the Ethics 
Committee of the University Hospital of Salamanca. Need for informed consent for 
immunostaining analysis from stored tissue from patients with liver cancer was waived by 
the Ethical Committee. A portion of each liver biopsy was fixed in 10% formalin and 
stained with haematoxylin-eosin and Masson’s trichrome for standard histopathological 
interpretation. Immunostaining of p38γ was performed with an antibody from R&D 
(AF1347; 1:250).
For the analysis of liver mRNA levels, the study population included 2 groups. One 
group consisted of obese adult patients with body mass index (BMI) ≥ 35kg/m2 and a 
liver biopsy compatible with NAFLD who underwent elective bariatric surgery (n=79). 
The second group consisted of individuals with BMI < 35kg/m2 who underwent 
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laparoscopic cholecystectomy for cholelithiasis (n= 30). Participants were excluded if 
they had a history of alcohol use disorders or excessive alcohol consumption (>30g/day 
in men and > 20g/day in women), chronic hepatitis C or B, or if laboratory and/or 
histopathological data showed causes of liver disease other than NAFLD. The study was 
approved by the Ethics Committee of the University Hospital of Salamanca and all 
subjects provided written informed consent to undergo liver biopsy under direct vision 
during surgery. All patients signed written informed consent for participation. Data were 
collected on demographic information (age, sex, and ethnicity), anthropomorphic 
measurements (BMI), smoking and alcohol history, coexisting medical conditions, and 
medication use. Before surgery, fasting venous blood samples were collected for 
determination of complete cell blood count, total bilirubin, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), total cholesterol, high-density lipoprotein, low-
density lipoprotein, triglycerides, creatinine, glucose, and albumin. Baseline 
characteristics of these groups are listed in Appendix Table 2. Kaplan-Meier survival 
curves of patients stratified by low or high expression of p38γ were obtained and plotted 
from  Human Protein Atlas database.
Animal maintenance and treatments
Mice were housed in a pathogen-free animal facility under a 12 h light/dark cycle at 
constant temperature and humidity, and fed standard rodent chow and water ad libitum. 
For all studies, we employed p38γLoxP (B6.129-Mapk12tm1), p38LoxP (B6.129-
Mapk13tm1)20, AblCRE (B6.Cg-Tg(Alb-cre)21Mgn/J)21 and whole body knock-out 
mice for p38γ. Mice were backcrossed for at least 10 generations in C57BL/6. Cdk1-lox; 
Cdk2-KO mice, cMYCtg and LIKKγ KO were described previously22-24. Genotypes were 
determined by polymerase chain reaction (PCR). All experiments were performed with 
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males. Experiments involving animals were conducted in accordance with the Guide for 
the Care and Use of Laboratory Animals and approved by the CNIC Animal Care and 
Use Committee. Maximal tumour size permitted was 15 mm.
For long-term studies of liver tumour development and Kaplan–Meier analysis different 
protocols were assessed: i) 15-day-old mice received a single intraperitoneal (i.p.) 
injection of diethylnitrosamine (DEN; Sigma-Aldrich) dissolved in saline at a dose of 50 
mg/kg body weight. Pirfenidone (CAS: 53179-13-8; eBioChem) was administrated in 
drinking water at 2 g/l starting at 7 months after DEN injection and continuing for 3 
months. Mice in one randomly pre-assigned group were sacrificed at 1 or 6 months after 
DEN administration for histological and biochemical analyses. Age-matched mice in a 
second group were used to assess mortality. For short-term studies evaluating DEN-
induced hepatic injury and compensatory proliferation, adult mice were treated with 
DEN by a single i.p. injection at a dose of 100 mg/kg of body weight and sacrificed 2 h 
later. ii) Streptozotocin was i.p. injected (60 mg/g) into mice at 1.5 days after birth. All 
mice were fed in HFD after weaning and histopathological studies were assessed at 27 
weeks of age. iii) Carbon tetrachloride was injected i.p. in adult mice 3 times per week 
during 16 weeks. After the treatment, mice were sacrificed for histopathological and 
biochemical studies and tumour analysis.
For partial hepatectomy (PHx), adult mice were anaesthetized using a mixture of 
isoflurane/oxygen. Seventy percent of the liver was excised which involves removal of 
the medial and left lateral lobes (used for histological and biochemical analyses). Liver 
proliferation, regeneration and histological and biochemical analysis were performed at 
48 h and 15 days after PHx.
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Immunohistochemical analyses
Liver and tumour tissues were fixed with phosphate-buffered 10% formalin and 
embedded in paraffin. Sections of 5 µm were stained with haematoxylin and eosin (H&E) 
for histopathological examination. Cell proliferation was assessed by 
immunohistochemical staining for Ki67 (ab15580, 1:100; Abcam), BrdU (ab6326, 1:100; 
Abcam), and phospho-Rb (S795) (#9301, 1:100; Cell Signaling Technology).
BrdU treatment
Hepatocytes were labelled with BrdU in vivo 48 hours after PHx by i.p. injection of 2 mg 
BrdU. After 2 hours, mice were sacrificed and livers extracted. BrdU labelling was done 
according to the specification of the manufacturer (BD Pharmingen™ APC-BrdU Flow 
Kits). 
Assessment of HCC by magnetic resonance imaging
Tumours were monitored by MRI using i.v. administered gadoxetate disodium 
(Primovist®; Bayer Healthcare) as contrast medium to enhance focal hepatic tumours. 
Tumour volume was measured using OsiriX software (Pixmeo, Switzerland). 3D 
gradient echovolumetric imaging with minimum TR/TE (3/1.5 ms), 20º flip angle and 
isotropic 150 µm spatial resolution, totalling 6 minutes acquisition time, were acquired 
around 10 minutes after Primovist injection (2 mg/kg body weight) via the tail vein. 
Images were acquired on an actively shielded 7 T horizontal scanner (Agilent, Santa 
Clara, CA) equipped with MM2 electronics, a 115/60 gradient insert coil, and a 1H 
circular-polarization, transmit-receive volume coil of 35mm inner diameter and 30mm 
active length, built by Neos Biotec (Pamplona, Spain). Before contrast injection, each 
mouse was anaesthetized by inhalation of isoflurane/oxygen (2-4%) and monitored by 
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breathing rhythm and temperature (Model 1024, SA Instruments, NY). Animals were 
positioned supine on a customized bed with a built-in nose cone supplying inhalatory 
anaesthesia (1-2%) and kept at 35-37ºC by warm airflow throughout the experiment. 
After sacrifice, livers were harvested, weighed, and the number of visible tumours 
counted macroscopically and measured with a calliper. The figure shows axial slices 
extracted from the 3D volume dataset. Tumours were harvested and frozen for 
biochemical analyses. For liver analysis, the largest lobe was fixed in formalin and 
embedded in paraffin. Sections were stained with H&E and examined microscopically.
Biochemical analysis
Total hepatic proteins were extracted from 30 mg frozen liver or tumour tissue using 500 
µl of lysis buffer containing 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 
mM NaF, 1 mM sodium glycerophosphate, 5 mM pyrophosphate, 0.27 M sucrose, 1% 
Triton X-100, 0.1 mM PMSF, 0.1% β-mercaptoethanol, 1 mM sodium orthovanadate, 1 
µg/ml leupeptin and 1 µg/ml aprotinin. Proteins were separated by SDS-polyacrylamide 
gel electrophoresis and transferred onto 0.2 μm nitrocellulose membranes (Bio Rad). 
Membranes were blotted with primary antibodies targeting p38 (#9212, 1:1000; Cell 
Signaling Technology), p38γ (#2307, 1:5000; Cell Signaling Technology), a previously 
described p38γ antibody used for IP19, phospho-p38 T180/Y182 (#921, 1:1000; Cell 
Signaling Technology), Rb (#9313, 1:1000; Cell Signaling Technology), phospho-Rb Ser 
807/811 (#8516, 1:1000; Cell Signaling Technology), CDK2 ((78B2) #2546, 1:1000 
Cell Signaling Technology), PCNA (ab1897, 1:1000; Abcam), vinculin (V4505, 1:1000; 
Sigma), and GAPDH (G9245, 1:1000; Sigma). Membranes were incubated with an 
appropriate horseradish peroxidase-conjugated secondary antibody (GE Healthcare) and 
developed using an enhanced chemiluminescent substrate (GE Healthcare). In western 
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blots each lane corresponds to a different mouse. 
Hepatic, cardiac, and renal injury was assessed from the levels of serum alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), 
creatinine, alkaline phosphatase, and total bilirubin; all measurements were performed at 
the CNIC Animal Facility Unit.
Kinase assay
For the competitive kinase assays to evaluate the cooperation between CDK2 and p38γ, 
we used 0.5 μg of total protein and 0.5 μg of each kinase per reaction (Rb only, Rb+p38
γ, Rb+CDK2/cyclin A, Rb+p38γ+CDK2/cyclin A). We added 100 μM ATP to each 
reaction at 30 ºC for 15 min. To find all the residues phosphorylated by CDK2 and p38γ, 
we used 2 μg of total protein and 1 μg of each kinase per reaction (Rb only, Rb+p38γ, 
Rb+CDK2/cyclin A, Rb+p38γ+CDK2/cyclin A). We added 100 μM ATP to each 
reaction at 30 ºC for 60 min.
Reactions were run on ExpressPlusTM PAGE acrylamide gels from GenScript, stained, 
and bands corresponding to Rb were then excised and analysed by mass spectrometry to 
identify phosphopeptides8.
RNA isolation and quantitative real-time-PCR analysis 
Total RNA was isolated from liver and tumour tissue with the RNeasy Mini Kit (Qiagen) 
with on-column DNase I digestion. RNA was quantified using a NanoDrop 
spectrophotometer. Complementary DNA synthesis was carried out using the High-
Capacity complementary DNA Reverse Transcription Kit (Applied Biosystems). 
Expression of the housekeeping genes 18S and GAPDH was used for normalization. RT-
qPCR was performed using Fast SYBR Green (Applied Biosystem) on a 7900HT Fast 
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Real-time PCR system (Applied Biosystem). Primer sequences were as follows (F. 
forward; R. reverse):
GAPDH F: TGAAGCAGGCATCTGAGGG
GAPDH R: CGAAGGTGGAAGAGTGGGA 
18s F: CAGCTCCAAGCGTTCCTGG
18s R: GGCCTTCAATTACAGTCGTCTTC 
CycD1 F: GGTCCATAGTGACGGTCAGGT
CycD1 R:-GCGTACCCTGACACCAATCTC
CycE F: GCCTTCACCATTCATGTGGAT
CycE R: TTGCTGCGGGTAAAGAGACAG
CycA1 F. GTGGCTCCGACCTTTCAGTC
CycA1 R: CACAGTCTTGTCAATCTTGGCA 
Rb1 F: CCGTTTTCATGCAGAGACTAAA    
Rb1 R: GAGGTATTGGTGACAAGGTAGGA 
CDK1 F: AGAAGGTACTTACGGTGTGGT
CDK1 R: GAGAGATTTCCCGAATTGCAGT
CDK2 F: CCTGCTCATTAATGCAGAGGG
CDK2 R: GTGCTGGGTACACACTAGGTG
CDK4 F: ATGGCTGCCACTCGATATGAA
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CDK4 R: TCCTCCATTAGGAACTCTCACAC
hCOL1A F: GAGGGCCAAGACGAAGACATC
hCOL1A R: CAGATCACGTCATCGCACAAC
Cell lines and proliferation and transfection assays
Hepatocellular carcinoma (HCC) cell lines derived from human patients (HepG2, Huh7, 
Snu354, Snu398 and Snu449, NCBI Biosample) and wild-type human hepatocytes 
(HepaRG from Life Technologies). We first studied p38γ expression in cells derived 
from HCC patients to avoid the unjustified use of mice. Cell lines were tested for 
mycoplasma contamination by PCR. Cells were cultured in DMEM (Sigma, D5796) 
supplemented with 10% FBS (HyClone, SV30160.03), L-glutamine (Lonza, 20mM in 
0.85% NaCl) and penicillin/streptomycin (Lonza, DE17-602E; 10000 units of each 
antibiotic).
HepG2 and Snu398 cells were used for knock-down assays. shRNAs against p38γ were 
purchased from Dharmacon (V3LHS_636283 and V3LHS_636282).
To measure proliferation, HepG2 and Snu398 cells treated with shp38γ or shScramble
were seeded in 24-well plates at 15 × 104 cells/well at different FBS concentrations 
(0.1%, 0.2%, 2%, and 20%). Cells were counted after 48 hours of incubation.
For colony formation assays, 2 × 103 HepG2 and Snu398 treated with shp38γ or 
shScramble were seeded in a p100 Petri dish. After 2 weeks (without changing the 
medium) the colonies were fixed and stained with 0.1% crystal violet.
For soft agar assays, HepG2 shp38γ and HepG2 shScramble cells (105) were seeded in a 
p100 Petri dish between a base agar layer (0.5% agar, 1 × DMEM and 10% FBS) and a 
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top agarose solution (0.7% agar, 1 × DMEM and 20% FBS). The medium was 
replenished every 3 days. After 20 days, plates were stained with 0.5% crystal violet, and 
colonies were counted using a light microscope.
HA-Rb WT and HA-RbΔCDK plasmids (Addgene: 58905 and 58906 respectively) were 
transfected into HEK 293T cells using the calcium phosphate transfection method. Cells 
were lysed 36 hours post-transfection, and immunoprecipitation assays were performed. 
Lentivirus and adeno-associated virus production
Lentiviruses were produced as described4. Transient calcium phosphate co-transfection 
of HEK-293T cells was carried out with shCDK1 (RMM4532-EG12534), shCDK2 
(RMM4532-EG12534), shCDK4 (RMM4532-EG12567) or CDK6 (RMM4532-
EG12571) from Dharmacon, together with pΔ8.9 and pVSV-G packaging plasmids. 
Supernatants containing the lentiviral particles were collected 48 and 72 hours after 
removal of the calcium phosphate precipitate, centrifuged at 700 × g at 4 °C for 10 
minutes, and concentrated (×165) by ultracentrifugation for 2 hours at 121,986 × g at 4 
°C (Ultraclear Tubes, SW28 rotor and Optima L-100 XP Ultracentrifuge; Beckman). 
Viruses were resuspended in cold sterile PBS and titrated by qPCR.
AAV plasmids were cloned and propagated in the Stbl3 E. coli strain (Life 
Technologies). pCEFL Flag p38γ D129A and pCEFL-p38-D176AF327S25 were cloned 
into a liver-specific HRC-hAAT promoter plasmid26 to generate pAAV-HRC-hAAT-p38
γact (AAVp38*). AAV2/8-CAG-Cre-WPRE was obtained from Harvard University. 
These AAV plasmids were packaged into AAV-9 or AAV-8 capsids to specifically target 
the liver, produced by the Viral Vector Unit (CNIC) as described8. Adeno-associated 
viruses (serotypes AAV8 and AAV9) were produced in HEK-293T cells and collected 
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from the supernatant. Mice were injected in the tail vein with 1 × 1011 adenoviral 
particles suspended in PBS.
Computational Methods. Molecular Dynamics Simulations
Molecular Dynamics simulations (MD) were used to study the spontaneous binding of 
the inhibitor RO3306 to the ATP-binding sites of p38γ, CDK1, CDK2, and p38α. The 
spontaneous binding of the inhibitor pirfenidone to the p38γ ATP-binding site was also 
studied. The parameters for RO3306 and pirfenidone in the MD simulations were 
generated within the ANTECHAMBER module of AMBER 1627 using the general 
AMBER force field (GAFF), with partial charges set to fit the electrostatic potential 
generated at the HF/6-31G(d) level by the RESP model. The charges were calculated 
according to the Merz-Singh-Kollman scheme using Gaussian 09.
Many crystal structures are available for the homologues p38α and p38β. However, p38γ
has only been crystallized in the phosphorylated state and in the presence of an ATP 
derivative in the ATP-binding site (Protein Data Bank (PDB) accession number 1CM8). 
In this crystal structure, the loops corresponding to residues 34-39, 316-321, and 330-
334 were not resolved. For the MD simulations, we generated two models of p38γ using 
the SwissModel homology model server and 1CM8 (phosphorylated and ATP-bound 
state p38γ) and 3GP0 (inhibitor-bound state of p38β) as templates. MD simulations of 
CDK1 were carried out using PDB 5HQ0 as a reference, removing the crystallized 
ligand occupying the ATP-binding site. MD simulations of CDK2 were performed using 
PDB 3PXR, corresponding to the apo CDK2 state. For p38α, PDB 3GI3 was used as a 
reference for starting the MD simulations, removing the crystallized ligand occupying the 
ATP-binding site. In all cases, we placed RO3306 or pirfenidone in an arbitrary position 
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in the solvent region (more than 20 Å far from the ATP-binding site). From these 
coordinates, we began unrestrained conventional MD simulations (250 ns) followed by 
accelerated MD simulations (1500 ns for p38γ with RO3306, 2000 ns for CDK1 with 
RO3306, 2250 ns for CDK2 with RO3306, 2000 ns for p38α with RO3306, and 2000 ns 
for p38γ with pirfenidone) to allow the inhibitor to diffuse freely until it spontaneously 
associated with the protein surface, and finally targeted the ATP-binding site. Inhibitor 
binding was monitored throughout the MD simulations by plotting a selected distance 
between the hydrogen bond acceptor of the inhibitor and the backbone of a residue 
located at the ATP-binding site responsible for the recognition and stabilization of the 
inhibitor (Met105 for p38γ and p38α, and Leu83 for CDK1 and CDK2; see Extended 
Fig. 1 and 10). Short distances indicate binding of RO3306 in the ATP-binding site. 
Spontaneous binding to p38γ was observed in 5 out of 10 simulations (light purple, light 
and dark blue, light red, and teal in extended Fig. 1b); in the case of CDK1, spontaneous 
binding was observed in 2 out of 10 simulations (light blue and light pink). When binding 
occurs, RO3306 remains in the ATP-binding pocket for the rest of the MD simulation, 
thus indicating the strong affinity of the inhibitor towards p38γ and CDK1. In contrast, 
spontaneous binding does not occur in p38 or only in 1 out of 10 simulations in CDK2 
(see extended Fig. 1c). Comparison of the observed spontaneous binding events in 500 
ns of aMD simulation time for p38γ and p38 indicate that RO3306 has a higher affinity 
towards p38γ (19.7 % and 5.5% of the simulation time RO3306 is bound p38γ and p38, 
respectively,  see extended Fig. 1d). 
Each system was immersed in a pre-equilibrated truncated octahedral box of water 
molecules with an internal offset distance of 10 Å, using the LEAP module. All systems 
were neutralized with explicit counterions (Na+ or Cl-). A two-stage geometry 
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optimization approach was performed. First, a short minimization was made of the water 
molecule positions, with positional restraints on solute by a harmonic potential with a 
force constant of 500 kcal mol-1 Å-2. The second stage was an unrestrained minimization 
of all the atoms in the simulation cell. The systems were then gently heated through six 
50 ps steps, each increasing the temperature by 50 K (0-300 K) under constant-volume 
and using periodic-boundary conditions and the particle-mesh Ewald approach to 
introduce long-range electrostatic effects. For these steps, an 8 Å cutoff was applied to 
Lennard-Jones and electrostatic interactions. Bonds involving hydrogen were constrained 
with the SHAKE algorithm. Harmonic restraints of 10 kcal mol-1 were applied to the 
solute, and the Langevin equilibration scheme is used to control and equalize the 
temperature. The time step was kept at 2 fs during the heating stages, allowing potential 
inhomogeneities to self-adjust. Each system was then equilibrated for 2 ns with a 2 fs 
timestep at a constant 1 atm pressure. Finally, a 250 ns conventional MD trajectory at 
constant volume and temperature (300 K) was collected, followed by ten replicas of 
1500 ns of dual-boost accelerated Molecular Dynamics (aMD)28,29 for p38γ in the 
presence of RO3306, ten replicas of 2000 ns of aMD for CDK1 in the presence of 
RO3306, ten replicas of 2250 ns of aMD for CDK2 in the presence of RO3306, ten 
replicas of 2000 ns of aMD for p38α in the presence of RO3306, and five replicas of 
2000 ns of aMD for p38γ in the presence of pirfenidone. Gathering a total of 15 μs of 
aMD for p38γ, 20 μs of aMD for CDK1, 22.5 μs of aMD for CDK2, and 20 μs of aMD 
for p38α, all of them with RO3306, and 10 μs of aMD for p38γ with pirfenidone. These 
long timescale unconstrained aMD simulations were performed with the aim of capturing 
a number of spontaneous binding events. aMD enhances the conformational sampling of 
biomolecules by adding a non-negative boost potential to the system when the system 
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potential is lower than a reference energy:
,               ,
,  , (1)
where  is the original potential, E is the reference energy, and  is the modified potential. 
In the simplest form, the boost potential,  is given by
 , (2)
where α is the acceleration factor. As the acceleration factor α decreases, the energy 
surface is flattened more and biomolecular transitions between the low-energy states are 
increased. 
Here, a total boost potential is applied to all atoms in the system in addition to a more 
aggressive dihedral boost, i.e., (Edihed, αdihed; Etotal, αtotal), within the dual-boost aMD 
approach. The acceleration parameters used in this study are as follows:
Edihed = Vdihed_avg + 3.5 × Nres, αdihed= 3.5 × Nres/5;
Etotal = Vtotal_avg + 0.2 × Natoms, αtotal = 0.2 × Natoms, (3)
where Nres is the number of protein residues, Natoms is the total number of atoms, and 
Vdihed_avg and Vtotal_avg are the average dihedral and total potential energies calculated from 
250 ns cMD simulations, respectively.
Data availability
The datasets supporting the findings of this study are available within the paper and its 
Supplementary Information. Source Data (gels and graphs) for Figs. 1–4 and Extended 
Data Figs. 1–10 are provided with the online version of the paper. There is no restriction 
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on data availability.
Statistical analysis and reproducibility
Data are expressed as means ± SEM. Differences were analysed by Student’s t-test, with 
significance assigned at p values <0.05. Fisher’s exact test was used to compare HCC 
incidence. The Wilcoxon-Mann-Whitney rank sum test was used to calculate the 
statistical significance of the observed differences between groups with different 
variances. The log-rank test was used to assess significance in the Kaplan–Meier 
analysis. GraphPad Prism version 5 software was used for calculations.
Animal sample size estimates were determined using power calculations. GraphPad 
Prism version 5 software was used for statistical analyses. Unpaired t-test were used to 
determine the power (a = 0.05, two-tailed). We observed many statistically significant 
effects in the data, indicating that the effective sample size was sufficient for studying the 
phenomena of interest. The mice experiments were randomized. Mice were grouped 
based on gender (male), genotype, treatments, weight and age, and randomly selected. 
We were blinded to allocation during experiments and outcome assessment. For in vivo
experiments, an investigator treated mice and collected the tissue samples. These samples 
were assigned code numbers. The analyses, including qPCR, immunohistochemistory 
staining, western blotting, were performed by another independent investigator.
Experiments were repeated two to three times. All attempts at replication were 
successful.
Figure 1a-d, Representative of at least three independent experiments. e, Data are 
mean ± SEM. n=3-5 fields from AlbCRE mice 0h n=3, 48h n=5; AlbCRE-p38γ mice 0h 
n=5, 48 n=7 mice; ***, P<0.001.  Comparisons were made by one-way ANOVA 
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coupled to the Bonferroni post-test. f, Data are mean ± SEM n=2-5 fields from AlbCRE 
mice 0h n=4, 48h n=7; AlbCRE-p38γ mice 0h n=4, 48 n=6 mice; **, P<0.01; ***, 
P<0.001 . Comparisons were made by one-way ANOVA coupled to the Bonferroni post-
test.  g,  Representative of at least three independent experiments. 1h, Data are 
mean ± SEM. AlbCRE n=3, AlbCRE-p38γ n=8 mice; ***, P<0.001. Comparisons were 
made by the two-sided Student t-test
Figure 2a-b, Representative of at least three independent experiments. c, Data are 
mean ± SEM. n= 4-5 fields from AlbCRE 0h n=7, 48h n=7; CDK1/2 KO 0h n=3, 48h 
n=3; CDK1/2 KO AAV p38γ* 0h n=4, 48h n=4 mice; *, P<0.05. Comparisons were 
made by one-way ANOVA coupled to Kruskal-Wallis post-tests. d, Data are 
mean ± SEM n= 3-5 fields from AlbCRE mice 0h n=7, 48h n=7; AlbCRE-p38γ 0h n=3, 
48 n=3; AlbCRE-p38γ AAV p38γ* 0h n=3, 48h n=3; *, P<0.05. Comparisons were 
made by one-way ANOVA coupled to Kruskal-Wallis post-tests.
Figure 3a Immuno-histochemistry was performed in two independent experiments. b,
Linear relationships from n=107 individuals tested by Pearson´s correlation; P<0.001. c, 
Kaplan-Meier survival curves of patients stratified by low or high expression of p38 , 
n=372 individuals; (Mantel-Cox log-rank test); P=3.9E-3. e, Data are mean ± SEM
(Mann Whitney U test) and f,  (two-sided Student t-test) in AlbCRE n=11, AlbCRE-p38
γ n=5. g, Kaplan-Meier analysis of survival in DEN-treated AlbCRE n=10 and AlbCRE-
p38γ n=11 mice; (Mantel-Cox log-rank test); **, P<0.01.
Figure 4a, Representative of at least three independent experiments. b, Data are 
mean ± SEM. AlbCre untreated 0h n=10 ; 48h n=5; AlbCRE-p38γ untreated 0h n=10; 
48h n=7 and AlbCre 0h n=10, 48h n=10;  AlbCRE-p38γ 0h n=17, 48h n=10 pirfenidone-
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treated mice; (one way ANOVA); ***, P<0.001. c, Representative of at least three 
independent experiments. d, Data are mean ± SEM. Tumour number control n=20, 
Pirfenidone n=13; total tumour volume control n=18, Pirfenidone n=13 and maximum 
tumour control n=18, Pirfenidone n=13. Mann-Whitney test; *, P<0.05. e, Kaplan-Meier 
analysis of survival. Mantel-Cox log-rank test; ***, P<0.001; Control n=6, Pirfenidone-
treated n=9 mice. f, Representative of at least three independent experiments. Each lane 
corresponds to a different liver or tumour sample. 
EXTENDED DATA FIGURE LEGENDS
Extended data Figure 1: Similarities between p38s and CDKs
a, Phylogenetic tree of murine CMGC group kinases: CDK family is boxed in orange, 
and p38 family in green. b-c, Plot of the distance (in Å) between RO3306 and the ATP-
binding site along the 10 accelerated MD simulations (aMD) of CDK1 and p38γ (b), p38
α and CDK2 (c), together with representative RO3306-bound conformations. 
Spontaneous binding of RO3306 occurs in: 5/10 simulations in p38γ, 2/10 in CDK1, 
0/10 in p38α, and 1/10 in CDK2. d Comparison of spontaneous binding events observed 
in 500 ns of aMD simulation time for p38γ and p38. e, Representative binding pathway 
obtained from aMD simulations of RO3306 for p38γ and CDK1. f, p38γ phosphorylation 
sites detected in Rb by in vitro kinase assay followed by mass spectrometry analysis.
Extended data Figure 2: MS analysis of in vitro phosphorylation of Rb by 
active p38γ or CDK2/CyclinA. CDKs and Cyclins mRNA expression in AlbCRE-
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p38γ mice.
a, In an in vitro kinase assay, recombinant human Rb protein (2 μg) was 
incubated alone or in the presence of p38γ or CDK2/cyclinA kinases (1 μg) and 
0.2 mM of cold ATP for 60 min. The panels show interpreted MS/MS spectra 
demonstrating the phosphorylation of the indicated sites in Rb (in lower case 
letters). The table shows the total spectral counts of the peptides where each 
phosphosite was identified. The data are representative of at least three independent 
experiments. No phosphopeptides were identified in the negative control without 
kinase. b, Quantitative PCR in livers from AlbCRE and AlbCRE-p38γ mice. Expression 
was normalized to GAPDH. Data are shown as mean ± SEM (n=15 mice for 
CDK1/2/4/6 and n=6 mice for Cyclins A1, D1 and E1). *, P<0.05; **, P<0.01; ***, 
P<0.001. Comparisons were made by one-way ANOVA coupled to Bonferroni’s post-
tests.
Extended data Figure 3: Hepatocyte expression of active p38γ reverts the liver 
proliferation in AlbCRE-p38γ mice
AlbCRE control mice, AlbCRE-p38γ mice and AlbCRE-p38γ mice infected with AAV 
expressing active p38γ (AlbCRE-p38γ AAVp38γ*) were subjected to two-thirds PHx or 
SHAM procedure. a, Gain liver mass, liver weight and liver/body mass ratio were 
measured after 15 days of PHx and expressed as the mean ± SEM (Gain liver mass 
AlbCRE n=8 and AlbCRE-p38γ n=5 mice; Liver/body weight AlbCRE n=9 and AlbCRE-
p38γ n=5 mice; Liver weight AlbCRE n=9 and AlbCRE-p38γ n=5 mice). *, P<0.05; **, 
P<0.01. Comparisons were made by two-sided Student’s t-test b, BrdU incorporation 
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quantified by cytometry. Data are mean ± SEM (n=3). ***, P<0.001; *, P<0.05; **, 
P<0.01. Comparisons were made by one-way ANOVA coupled to Bonferroni’s post-
tests. c, pRb Ser795 immunostaining quantified in livers 48 hours after PHx. 
Representative images (left). Scale bar: 100μm. Data are mean ± SEM (right) (n=5 
mice).  ***, P<0.001. Comparisons were made by one-way ANOVA coupled to 
Bonferroni’s post-tests. d, Immunoblot analysis of liver extracts with antibodies against 
phospho-Rb S807/811, Rb, p38γ, and vinculin (as a loading control), each lane 
corresponds to a different mouse. The data are representative of at least three 
independent experiments. e, Liver/tibia length ratio, expressed as mean ± SEM (n=6 
mice). *, P<0.05; **, P<0.01. Comparisons were made by one-way ANOVA coupled to 
Bonferroni’s post-tests. f, Hepatocyte proliferation analysed by Ki67 immunostaining 48 
hours after PHx. Representative images (left). Scale bar: 100μm. Ki67 positive cells, 
shown as mean ± SEM (right). Comparisons were made by one-way ANOVA coupled to 
Kruskal-Wallis’ test. g, WT infected with AAV expressing active p38γ (AAVp38γ*) or 
active p38 (AAVp38*) were subjected to two-thirds PHx. Rb phosphorylation at the 
specified residues were assessed by western blot 48h after PHx. Antibody anti HA-tag 
was used as control of liver infection by AAVp38* and AAVp38*, each lane 
corresponds to a different mouse. The data are representative of at least three 
independent experiments. h, Proliferation 48h after PHx were studied by  Ki67 
immunostaining (upper panel) or BrdU incorporation (lower panel) in 
immunohistological liver section. Scale bar: 100 μm. Ki67 and BrdU positive cells, 
shown as mean ± SEM (n=5 counted areas from AlbCRE 0h n= 4, 48h n= 4; AlbCRE-
p38γ 0h n=3, 48h n=3;  AlbCRE-p38γ AAVp38γ* 0h n=3, 48h n=3 mice, n=5-25 
counted areas from WT AAVp38γ* n=4 and WT AAVp38* n=2 mice). ***, P<0.001; 
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*, P<0.05; **, P<0.01. Comparisons were made by two-sided Student’s t-test.
Extended data Figure 4: p38 partially compensates the lack of p38γ.
a, Kaplan-Meier analysis of survival in PHx-treated AlbCRE and AlbCRE-p38γ mice. 
n=20 mice per genotype. Mantel-Cox log-rank test were used. b, Liver Rb 
phosphorylation was studied in AlbCRE and AlbCRE-p38γ mice by western blotting 
with the indicated antibody 48, 60 and 72h after PHx, each lane corresponds to a 
different mouse. The data are representative of at least three independent experiments. 
c, p38 expression was studied by RT-PCR at different time points after PHx and the 
increment of its expression was represented (AlbCRE n=7 and AlbCRE-p38γ n=6 mice). 
Comparisons were made by two-sided Student’s t-test. d-h, AlbCRE control mice and 
AlbCRE-p38γ mice were subjected to two-thirds PHx or SHAM procedure and 
analysed after 48, 60 or 72 hours. d, Kaplan-Meier analysis of survival analysed by 
Mantel-Cox log-rank test. e, Immunoblot analysis of liver extracts from AlbCRE-p38γ
mice with antibodies against phospho-Rb S807/811, Rb, p38γ, and vinculin (loading 
control), each lane corresponds to a different mouse. The data are representative of at 
least three independent experiments. f-g, Hepatocyte proliferation were analysed by f, 
BrdU incorporation (two-sided Student’s t-test; **, P< 0.05) g, or Ki67 immunostaining 
(two-sided Student t test with Welch's correction; *, P< 0.01) at 48h after PHx in 
AlbCRE-p38γ (n=3) and AlbCRE-p38γ (n=3) mice. h, Hepatocyte proliferation by
BrdU incorporation was analyse 60 and 72h post PHx in AlbCRE mice (n=9 at 60h and 
n=7 at 72h), AlbCRE-p38γ (n=6 at 60h and 72h) and AlbCRE-p38γ (n=3 at 60h and 
72h) mice. Comparisons were made by one-way ANOVA coupled to Bonferroni’s post-
tests; ***, P<0.001. Representative images (left). Scale bar: 50 μm. Ki67 and BrdU 
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positive cells are quantified as mean ± SEM (right) (n=5 counted areas from the specified 
number of mice). 
Extended data Figure 5: Reduced epithelial proliferation and Rb phosphorylation 
in the absence of p38γ after DSS treatment.
WT and p38 KO mice were treated for 6 days with DSS in the drinking water. a, 
Representative images showing the shortening of the colon after DSS treatment. b,
Immunohistochemical staining and BrdU quantification in colon tissue sections of DSS-
treated WT and p38 KO mice. c, Immunohistochemical staining and phospho-Rb S795 
quantification. Quantification is shown as mean ± SEM. n=5-10 fields from WT H2O n= 
5, DSS n=7; p38 KO H2O n=5, DSS n=9 mice; **, P<0.01; *** P<0.001. Comparisons 
were made by one-way ANOVA couple with Bonferroni's Multiple Comparison test in b 
and c. Scale bar, 100 μm. d, Immunoblot analysis of Rb phosphorylation in intestine, 
detected with the indicated antibody, each lane corresponds to a different mouse. The 
data are representative of at least three independent experiments. 
Extended data Figure 6: p38γ and CDKs cooperate in the induction of Rb 
phosphorylation and liver proliferation. 
a, In vitro kinase assay, phosphorylation sites identified by mass spectrometry are 
underlined. b, Immunoblot analysis of CDK2 in p38γ immunoprecipitates from liver of 
AlbCRE-p38γ mice with or without infection with AAV expressing active p38γ
(AAVp38γ*). c, Immunoblot analysis of liver Rb expression in WT and CDK1/2 KO 
mice (AAV2/8-Cre-infected) in steady state. d, BrdU immunostaining analysis o after 
PHx. Quantification is shown as mean ± SEM. n=5 fields from 0h n= 4, 2h n=5, 8h n=5, 
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12h n=5, 24h n=5, 36h n=7, 48h n=14, 60h n=6, 72h n=4 mice. (one-way ANOVA 
couple with Bonferroni's Multiple Comparison test). e, Immunoblot analysis in livers 
from AlbCRE and AlbCRE-p38γ mice. f, Immunoprecipitation–immunoblot analysis of 
CDK2 interaction with WT and nonphosphorylatable Rb in HEK-293T cells transfected 
with human HA-Rb WT or HA-Rb CDK (nonphosphorylatable by CDKs). g-m, WT 
mice were injected with lentivirus containing shScramble or shRNA targeting CDK1/2 
(shCDK1/2) or CDK4/6 (shCDK4/6) with or without AAV expressing active p38γ
(AAV p38γ*). Mice were subjected to PHx or a SHAM procedure. g,k,l Immunoblot 
analysis. Hepatocyte proliferation analysed by Ki67 immunostaining 48 hours after PHx. 
Scale bar, 50 μm h, i, m Hepatocyte proliferation was analysed by Ki67 immunostaining 
48 hours after PHx. Scale bar, 100 μm. Ki67-positive cell quantification is shown as 
mean ± SEM. i, (n=5-10 counted areas from WT 0h n=2, 48h n=3; shCDK1/2 0h n=3, 
48h n=4; shCDK1/2 0h AAV p38γ* 0h n=4, 48h n=5 mice); ***, P<0.001. (one-way 
ANOVA couple with Bonferroni's Multiple Comparison test). m, (n=5 counted areas 
from n=5 mice). ***, P<0.001.  Comparisons were made by two-sided Student t test. In 
the western blots, each lane corresponds to a different mouse and are representative of at 
least three independent experiments. 
Extended data Figure 7: p38γ expression is increased in human HCC.
a, Percentage of HCC patients with mutations in p38γ, CDK1, and CDK2 and the 
number of HCC mutations in p38γ, CDK1, and CDK2. Data were obtained from the 
International Cancer Genome Consortium (data from 17/07/2017). b, Expression of p38
γ in human primary hepatocytes and in human HCC cell lines (Huh7, HepG2, Snu449 
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and Snu398) or other type of cancer cells (HTB77). c, Immunoblot analysis of phospho-
p38 and total p38 in liver extracts from mice lacking IKK in the liver (LIKKKO) and 
control littermates (WT) (left) and from c-MYC transgenic mice (cMYCtg) and WT 
counterparts (right). p38 phosphorylation was detected only in mice lacking IKK
specifically in the liver or overexpressing C-MYC. Vinculin served as a loading control. 
In the western blots each lane corresponds to a different mouse and are representative of 
at least three independent experiments. d, Immunohistochemical staining of p38γ in 
human HCC liver. Negative control, p38γ KO mice; Positive control, p38γ KO mice 
infected with human AAVp38γ. The chart shows stratification of p38γ expression in 
human liver samples as no expression, low, medium, and high expression (n=46 patients 
with HCC and n=11 healthy patients).
Extended data Figure 8: p38γ expression is necessary for Snu398 and HepG2 
proliferation.
a, Immunoblot analysis of Snu398 cells treated with lentiviral particles containing two 
p38γ-targeting shRNAs (B5 or G1) or shScramble. Representative western blot of at 
least three independent experiments. b, Growth of Snu398 cells infected with shp38γ or 
shScramble. Cells were plated and cultured for 2 days in medium supplemented with 
different serum concentrations. Relative cell number was measured by crystal violet 
staining. Data are mean ± SEM (n=12). ***, P<0.00. Comparisons were made by two-
way ANOVA. c, Colony formation assay of Snu398 cells infected with shp38γ or 
shScramble, representative images. d, Cells were grown in DMEM with 10% serum. The 
number of colonies with >10 cells was counted after 15 days. . Data are mean ± SEM 
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(n=3) and are representative of results from three independent experiments. **, P<0.01,
***, P<0.001. Comparisons were made by two-sided Student’s t-test. e, Immunoblot 
analysis in HepG2 cells treated with lentiviral particles containing a shRNA against p38γ
or scramble control. Representative western blot of at least three independent 
experiments. f, Growth of HepG2 cells infected with shp38γ or shScramble. Cells were 
plated and cultured for 2 days in medium supplemented with different serum 
concentrations. Relative cell numbers were measured by crystal violet staining. Data are 
mean ± SEM (n=3) and are representative of results from three independent experiments. 
***, P<0.001. Comparisons were made by two-way ANOVA. g, Colony formation 
assay of HepG2 cells infected with shp38γ or shScramble, representative images. Cells 
were grown in DMEM with 10% serum. The number of colonies with >10 cells was
counted after 15 days. Representative images are shown. Data are mean ± SEM (n=3). 
***, P<0.001. Comparisons were made by two-sided Student’s t-test. h, Soft agar assay 
of HepG2 cells infected with shp38γ or shScramble. Cells were grown in DMEM with 
10% serum. The number of colonies with >10 cells was counted after 20 days. Data are 
mean ± SEM (n=12). ***, P<0.001. Comparisons were made by t Mann-Whitney test.
Extended data Figure 9: Alb-Cre p38 mice are protected against CCl4-induced 
liver damage and HCC-induced by type 1 diabetes.
a, Immunoprecipitation–immunoblot analysis of phospho and total p38γ in liver extracts 
from AlbCRE control mice, showing p38γ activation upon acute DEN treatment (100 
mg/kg for 2 hours). Liver lysates (2 mg) were immunoprecipitated with anti-p38γ
antibody followed by immunoblotting as indicated. b, Immunoblot analysis of Rb 
S807/811 phosphorylation and PCNA content in liver of AlbCRE mice and Alb-Cre p38
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mice 1 month after DEN injection. Vinculin is shown as a loading control. c, 
Representative images of Ki67 immunohistochemistry in livers of AlbCRE and Alb-Cre
p38 mice 8 months after DEN injection. Scale bar, 500μm. Data are mean ± SEM. n=10 
fields in n=7 mice; (two-sided Student t-test); *** P<0.001. d-e, AlbCRE and Alb-Cre
p38 mice were injected with 2 ml/kg of CCl4 (v/v) in 20% corn oil, three times per week 
for 14 weeks. All mice were fed a HFD. d, Representative images of liver tumours (left 
panel) and quantification of tumour size (right panel); *** P <0.001; Comparisons were 
made by two tail Student’s t-test with Welch's correction. b, Immunohistochemical 
staining and Ki67 quantification on liver tissue sections; *** P<0.001; Comparisons 
were made by two-sided Student’s t-test. Scale bar, 100 μm. Quantification is shown as 
mean ± SEM. n=5 fields from n=9 mice. c-d, Streptozotocin was subcutaneously 
injected (60 mg/g) into AlbCRE and AlbCre-p38 mice at 1.5 days after birth. All mice 
were fed a HFD and histopathologically assessed at 27 weeks of age. c,
Immunohistochemical staining for phosphor-Rb S795 on liver tissue sections (AlbCRE 
n=5, AlbCre-p38 n=5 mice); *** P<0.001; Comparisons were made by two tail 
Student’s t-test with Welch's correction. Scale bar, 100 μm.and d, Ki67 (AlbCRE n=4, 
AlbCre-p38 n=5 mice). Quantification is shown as mean ± SEM. n=2-6. Scale bar, 100 
μm..** P<0.01; Comparisons were made by two-sided Student’s t-test. 
Extended data Figure 10: p38γ deletion or inhibition protects against DEN-
induced HCC.
a,  Upper panel, representative conformations of p38γ and the ATP-binding site of p38α, 
both with the inhibitor pirfenidone bound (in purple), extracted from the MD 
simulations. Central panel, activation loop is shown in teal and other relevant ATP-
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binding site residues in light blue. Lower panel, plot of distance (in Å) between the 
oxygen of the pirfenidone carbonyl group and the amide backbone of p38γ Met105 
during the MD simulations for the 5 replicas (shown in different colours). Short 
distances indicate binding of pirfenidone in the ATP-binding site. Spontaneous binding of 
pirfenidone to p38γ was observed in 1 out of 5 simulations. b, Western blot of 
phosphorylated Rb. 10 μM BIRB796 or Pirfenidone for 30 min before the assay. 
Representative western blot of at least three independent experiments. c, WT mice were 
treated with or without pirfenidone for 10 weeks and blood concentrations of selected 
parameters were assayed: Alanine aminotransferase (ALT), as a readout of hepatic injury
(comparisons were made by two-sided Student’s t-test). Aspartate aminotransferase 
(AST), as a readout of hepatic and cardiac injury (comparisons were made by two-sided 
Student’s t-test). Total bilirubin, as a readout of hepatic injury (comparisons were made 
by Mann Whitney test). Alkaline phosphatase, as a readout of hepatic and cardiac injury
(comparisons were made by Mann Whitney test). Creatine kinase (CK) and creatinine, as 
a readout of cardiac and renal injury (comparisons were made by Mann Whitney test). 
All data are mean ± SD (n=10 mice). d, Immunoblot analysis of p38 in liver and tumour 
samples after AAVCRE infection. Representative western blot of at least three 
independent experiments. e, Number of tumours and tumour size analysed at the end of 
the experiment. Data are mean ± SEM. n=10 untreated and n=20 cre-treated mice; * 
P<0.05.; ***, P<0.001. (comparisons were made by two-sided Student’s t-test with 
Welch´s correction). f, Representative contrast-enhanced MRI results from mice 7 
months after DEN injection with or without CRE-mediated p38 deletion. The figure 
shows axial slices extracted from the 3D volume dataset. Arrowheads mark typical liver 
tumours. g, AAVCRE mediated deletion of p38γ protects against STZ-induced HCC. 
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Left panel indicates increased liver damage after STZ treatment; ***; P<0.001 
(Comparisons were made by Student’s t-test). Right panel shows tumour size that was 
analysed at the end of the experiment; *, P<0.05 (Comparisons were made by one-way 
ANOVA coupled to the Bonferroni post-test) Data are mean ± SEM. n=10 untreated 
and n=20 CRE-excinded-treated mice. In the western blots, each lane corresponds to a 
different mouse.
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